Title |
Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
|
---|---|
Published in |
Frontiers in oncology, April 2018
|
DOI | 10.3389/fonc.2018.00127 |
Pubmed ID | |
Authors |
Daniel Benitez-Ribas, Raquel Cabezón, Georgina Flórez-Grau, Mari Carmen Molero, Patricia Puerta, Antonio Guillen, E. Azucena González-Navarro, Sonia Paco, Angel M. Carcaboso, Vicente Santa-Maria Lopez, Ofelia Cruz, Carmen de Torres, Noelia Salvador, Manel Juan, Jaume Mora, Andres Morales La Madrid |
Abstract |
Diffuse intrinsic pontine glioma (DIPG) is a lethal brainstem tumor in children. Dendritic cells (DCs) have T-cell stimulatory capacity and, therefore, potential antitumor activity for disease control. DCs vaccines have been shown to reactivate tumor-specific T cells in both clinical and preclinical settings. We designed a phase Ib immunotherapy (IT) clinical trial with the use of autologous dendritic cells (ADCs) pulsed with an allogeneic tumors cell-lines lysate in patients with newly diagnosed DIPG after irradiation (radiation therapy). Nine patients with newly diagnosed DIPG met enrollment criteria. Autologous dendritic cell vaccines (ADCV) were prepared from monocytes obtained by leukapheresis. Five ADCV doses were administered intradermally during induction phase. In the absence of tumor progression, patients received three boosts of tumor lysate every 3 months during the maintenance phase. Vaccine fabrication was feasible in all patients included in the study. Non-specific KLH (9/9 patients) and specific (8/9 patients) antitumor response was identified by immunologic studies in peripheral blood mononuclear cells (PBMC). Immunological responses were also confirmed in the T lymphocytes isolated from the cerebrospinal fluid (CSF) of two patients. Vaccine administration resulted safe in all patients treated with this schema. These preliminary results demonstrate that ADCV preparation is feasible, safe, and generate a DIPG-specific immune response detected in PBMC and CSF. This strategy shows a promising backbone for future schemas of combination IT. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 25% |
United Kingdom | 1 | 25% |
Switzerland | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 58 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 19% |
Student > Master | 10 | 17% |
Student > Ph. D. Student | 7 | 12% |
Other | 6 | 10% |
Student > Bachelor | 5 | 9% |
Other | 6 | 10% |
Unknown | 13 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 19% |
Biochemistry, Genetics and Molecular Biology | 10 | 17% |
Immunology and Microbiology | 7 | 12% |
Agricultural and Biological Sciences | 5 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 7 | 12% |
Unknown | 16 | 28% |